Experts are urging the UK health authorities to recosider the recent decision against a nationwide prostate cancer screening programme after a study showed that using MRI after a positive PSA test could cut the need for biopsies by 50 % and speed up diagnoses. The proposal, championed by the PRISM panel, would target men with elevated PSA levels and reserve biopsies for those with clearly suspicious MRI findings. If adopted , the approach could reshape how the most common male cancer is detected in Britain.

PRISM panel recommends MRI after PSA , not straight to biopsy

The Prostate Imaging for Screening Magnetic Resonance Imaging (PRISM) recommendations call for an MRI scan to be offered immediately after a positive PSA result, before any biopsy is performed.. This step, according to the panel, would let clinicians act on lower PSA thresholds and identify cancers earlier . As David James of Prostate Cancer Research noted, “Screening policy must continue to evolve alongside innovation and the evidence base .”

Study of 1,900 men finds biopsies could be halved with MRI‑first pathway

Led by urology specialist Nikhil Mayor at Imperial College London, the review examined six studies involving more than 1,900 participants, of whom 1,426 received upfront MRI screening. The analysis concluded that a personalised MRI‑first protocol could reduce biopsies by roughly 50 % while detecting a comparable number of clinically significant cancers , effectively doubling the accuracy of positive tests.

Risk‑adjusted screening intervals proposed for black men and genetic carriers

The panel suggests starting routine screening at age 50 for the general male population, but invites black men from age 45 and recommends more frequent MRI for those with a known genetic predisposition. Men at low risk would be scanned every four to five years, whereas higher‑risk groups would have shorter intervals, aligning resources with the disease’s demographic patterns.

Unanswered: How will AI‑read MRI reports be regulated?

While the experts stress that biopsy decisions should not rely solely on AI interpretation of MRI scans, the report does not clraify what safeguards will govern AI use or how radiologists will be trained to read faster, simpler scans. Moreover, the UK National Screening Committee’s recent decission limits invitations to as few as 3,000 men, leaving a gap between the evidence and policy that remains to be bridged.

According to the source, the Department of Health and Social Care has yet to comment on the new evidence, and officials have previously rejected a broader screening programme, citing insufficient data. The Daily Mail has long campaigned for improved prostate diagnostics, arguing that MRI could free up treatment slots and reduce waiting lists.